Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report. Issue 13 (1st June 2021)

• Record Type: Journal Article
• Authors: Nakao, Akira; Inoue, Hiroyuki; Osaki, Yusuke; Hirano, Ryosuke; Harada, Taishi; Aoyama, Takashi; Igata, Fumiyasu; Fujita, Masaki
• Is Part Of: Thoracic cancer. Volume 12:Issue 13(2021)
• Page Start: 2039
• Page End: 2042
• Publication Date: 2021-06-01
• Subjects: cisplatin -- gemcitabine -- hypomagnesemia -- necitumumab -- squamous cell lung cancer; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13999
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: A 72‐year‐old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth‐line treatment. Tumor shrinkage was observed, but asymptomatic grade 4 hypomagnesemia occurred on day 8 of the second cycle. He received magnesium replenishment and hypomagnesemia recovered on day 40, but tumor progression was observed during the period of magnesium correction. Hypomagnesemia is known as a major adverse event of treatment with anti‐EGFR antibodies, but there have been no case reports of severe hypomagnesemia or its clinical course. Abstract : An unusual case in which we successfully corrected the grade 4 hypomagnesemia as a severe adverse event via intravenous supplementation in the treatment for squamous non‐small cell lung cancer. ​